Class 4 drug alert: certain Baxter Potassium Chloride containing intravenous infusions

Baxter Healthcare Limited has informed the MHRA that a quality defect has been identified with certain potassium chloride containing intravenous infusions where the front panel of a small number of infusion bags was found to be missing the red text. The red text highlights the presence of potassium chloride in the products formulation which is a risk-mitigating factor in the prevention of a potential mix-up with other solutions for infusion.

Further information, details of the affected batches and advice for healthcare professionals can be found on the MHRA website.